EXSCIENTIA
Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).
AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.1,2 Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones – and there is currently no cure.3
This exciting new partnership unites Exscientia's AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI.
The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD,4 targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.
Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia's Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD.
Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make novel drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.”
Expanding on this new relationship, Dr John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: "We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”
Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said:
“Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.”
ENDS
Notes to Editors:
About the NLRP3 inflammasome in the pathophysiology of Alzheimer’s disease (AD)
Inflammasomes are part of the innate immune system and are responsible for a wide range of inflammatory responses. In AD, activated NLRP3 inflammasome leads to the release of pro-inflammatory cytokine (IL-1 beta) and ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) speck into the intercellular space. The release of ASC specks from microglia promotes amyloid-beta aggregation in AD. The accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together result in neurodegeneration and cognitive decline that characterize AD.
About Exscientia
Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients.
About Centaur Chemist®
Centaur Chemist® is Exscientia’s solution to AI-driven drug design combining the latest AI-tech with the therapeutic experience of seasoned drug hunters. Driven by algorithms that mimic evolutionary design as well as deep learning to analyse complex information and active learning to extract insights from sparce, high-value datasets, Centaur Chemist® has been skilfully engineered to work with widest range of discovery data to ensure application to the widest range of discovery projects.
Centaur Biologist®
Centaur Biologist® supports the discovery and prioritisation of drug targets, ensuring that any candidate molecules developed will be aligned with key therapeutic objectives. With deep learning and vector embedding techniques Centaur Biologist® pinpoints trends and insights from big data and captures semantics that predict new unexpected associations.
For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI
About the ARUK-Oxford Drug Discovery Institute, University of Oxford
The Alzheimer’s Research UK Oxford Drug Discovery Institute is a drug discovery team, founded with funding from the charity Alzheimer’s Research UK, with the objective of accelerating the translation of basic science generated within universities towards therapeutic utility. The focus of the team is upon discovering treatments for the neurodegenerative diseases underlying dementia. Although Alzheimer’s disease is the most common cause of dementia and the charity bears its name, the remit of the ARUK-ODDI covers all diseases and mechanisms implicated in the different neurodegenerative diseases that contribute to dementia, including Alzheimer’s disease, Parkinson’s disease, vascular dementia and frontotemporal dementia. For more information, visit https://oxford-ddi.alzheimersresearchuk.org/about-the-institute/ .
References:
1 World Health Organization. Fact Sheet. Dementia. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia . Last accessed 10 February 2021
2 Alzheimer’s News Today. Available at: https://alzheimersnewstoday.com/alzheimers-disease-statistics/ . Last accessed 10 February 2021
3 NHS. Alzheimer’s Disease. Available at: https://www.nhs.uk/conditions/alzheimers-disease /. Last accessed 10 February 2021
4 Immunity’s flipside: Microglia promote Alzheimer’s pathology during inflammation. Available at: https://www.novusbio.com/antibody-news/immunitys-flipside-microglia-promote-alzheimers-pathology-during-inflammation . Last accessed 10 February 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005386/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom